Phase II news from FierceBiotech
NewsPipex acquires mid-stage RA program
Pipex Pharmaceuticals has acquired oral dnaJP1, a once-daily candidate for the treatment of rheumatoid arthritis which has completed a 160 patient Phase II clinical trial for the treatment of Read more...
Merck suspends trial enrollment
SurModics says that Merck informed the company that results reported in a recently published study comparing laser treatment and intravitreal injections of triamcinolone acetonide in patients with Read more...
Elan wins $55M judgment in patent scrap
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Read more...
Lilly pays $35M to land TransPharma pact
Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its Read more...
Jazz Pharma axes staffers after delaying two trials
Jazz Pharmaceuticals says it needs to extend the development time line for two key drug programs, a move that triggered a decision to lay off 33 workers, or eight percent of its workforce. In a Read more...
Novo Nordisk discontinues Phase III on disappointing results
Concluding that a late-stage trial of its experimental therapy to prevent bleeding in trauma patients was headed to a likely failure, Novo Nordisk discontinued the study of Read more...
Alexza panic drug fails proof-of-concept trial
One of Alexza Pharmaceuticals' drug candidates failed a key proof-of-concept trial, sending its stock into a swoon. The Phase IIa trial failed to meet either of its primary endpoints for AZ-002: its Read more...
Vertex shares rise on positive data for telaprevir
Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...
Exelixis gets $150M credit line
Exelixis has struck a $150 million financing deal with Deerfield Management. At Exelixis discretion, the developer can draw down the money as needed over the next 18 months in $15 million Read more...
Transgene to partner after cancer vax passes trial
France's Transgene is taking the wraps off of positive Phase IIb data for its experimental cancer vaccine, TG4010. The European trial of 148 patients saw progression-free survival of 44 percent of Read more...
| Press ReleasesPRESS RELEASE: Nabi Biopharmaceuticals Announces Successful Completion of NicVAX Phase 2b Trial Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Read more... PRESS RELEASE: Anesiva Initiates New Phase 2 Trial of Adlea Anesiva Initiates New Phase 2 Trial of Adlea for Pain Relief Following Knee Replacement Surgery Adlea May Provide Pain Relief Without Opiate-Like Side Effects For Several Months Following a Single Read more... PRESS RELEASE: Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis Results Show Improvements in RA Signs and Symptoms Compared to Placebo Trubion Pharmaceuticals today Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets